SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending following the successful completion of an At-The-Market share offering and the full funding of its pending acquisition of Iridium, with the community largely focusing on the company's ability to de-risk its capital structure and the upcoming shareholder vote on the merger.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is receiving attention following record fourth-quarter bookings and a significant backlog, which investors view as strong indicators of sustained demand for its electrical distribution equipment in data centers and grid infrastructure. While community sentiment is largely bullish on the company's fiscal 2027 growth guidance, some traders remain cautious about lingering overhead supply and the impact of institutional ownership.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending following the announcement that the final efficacy analysis of its Phase 3 ORIGIN 3 trial for TRUTAKNA met all prespecified endpoints in treating IgA nephropathy. The community is focused on the drug's potential for full FDA approval and its competitive profile, with many traders speculating on a short squeeze due to high short interest and a tightly held float.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors monitor expectations for the upcoming earnings report, with community discussion focused on its scalable photonics technology, government-backed contract progress, and the potential for commercial partnership announcements.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is experiencing significant volatility and downward pressure following heavy insider selling, including by the CEO, alongside broader market concerns about its high valuation and sector rotation. Investors remain divided, with some citing the company's strong growth in AI and defense contracts as a long-term buy opportunity, while others view the stock as overpriced and over-manipulated.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending primarily due to the presentation of positive Phase 3 data for plozasiran in patients with severe hypertriglyceridemia, which demonstrated significant reductions in triglycerides and acute pancreatitis events. While many traders are optimistic about the company's platform potential and future catalysts, others expressed frustration with price volatility and aggressive market-making activity in the options market.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's shares plummeted after the company reported a surprise second-quarter loss and missed revenue expectations. While retail sentiment remains optimistic due to the CEO's focus on turnaround initiatives and improved sales trends, many traders express skepticism regarding the company's long-term viability and high debt load.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Arbitrum is gaining momentum as the community monitors its role in Robinhood's blockchain and tokenization initiatives. Traders are expressing bullish sentiment regarding its ecosystem growth and potential for value appreciation, while some acknowledge the ongoing impact of periodic token unlocks on price action.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is seeing increased investor attention as traders speculate on a potential buyout, driven by the strong commercial performance of its core product and an expanding pipeline of next-generation therapies. While enthusiasm remains high regarding long-term potential, some shareholders express frustration with current stock volatility and the pace of strategic developments.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending as investors discuss the completed acquisition of Chain Technology and its intellectual property, which the community views as a foundational step for the Onyx neobank ecosystem. While some traders are optimistic about the potential for real-world adoption and institutional integration, others remain skeptical, citing historical price underperformance and concerns regarding token dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NFLX just got a nice vote of confidence from Wolfe Research.

They raised their price target from $84 to $95 and believe the weaker Q2 engagement was more about Netflix’s content schedule than weakening demand.

The data is pretty interesting: shows returning in Q3 generated roughly 1.3B hours of Top 10 viewing from prior seasons, compared to just 765M hours for the Q2 group.

Basically, the content slate gets much stronger from here.

Wolfe now expects a stronger second half of 2026 and solid 2027 guidance.

Nick

Racine milfort

StockTwits for iOS

Netflix Inc

 just got a nice vote of confidence from Wolfe Research.

They raised their price target from $84 to $95 and believe the weaker Q2 engagement was more about Netflix’s content schedule than weakening demand.

The data is pretty interesting: shows returning in Q3 generated roughly 1.3B hours of Top 10 viewing from prior seasons, compared to just 765M hours for the Q2 group.

Basically, the content slate gets much stronger from here.

Wolfe now expects a stronger second half of 2026 and solid 2027 guidance.